BPR-30221616

N/A

Report date: 2025/02/12 14:53:45
NME

Base Information

Drug NameBPR-30221616
Drug Alias NameBPR-30221616BPR30221616
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Brilliant Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Brilliant Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A